A Comparative Study of Biologic Regulation in US, Canada, Australia, Europe and Singapore

Abstract

Extensive research in chemistry, manufacturing, controls, preclinical science, and clinical trials is required when developing a novel biological medication. Drug reviewers in regulatory bodies throughout the world and all regulatory bodies are entrusted with determining whether research evidence establishes new drug product safety, effectiveness, and quality control in order to protect public health. Among the world every province has its own regulatory organization in charge of enforcing laws and regulations and developing guidelines for drug marketing. There are some particular requirements sets by regulatory authority that must be satisfied when submitting in the particular nation. The world is split into various approval procedures, it is pivotal for manufacturers to carefully assess market interest, expenditures, target zones, and regulatory standards before establishing biologics. Despite the existence and widespread adoption of an ICH-CTD standard format, some limitations are included. This article discusses the comparison considerations used for biological product approval in the United States, Canada, Europe, Australia, and Singapore.